Clinical trials: Neoplasm, Gastrointestinal
Colorectal Cancer
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen…
- Trial name
- NCT03035279
- Testing
- SC-006, ABBV-181
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- AbbVie
Breast Cancer, Prostate Cancer
Physical Activities by Technology Help (PATH)
PATH is a research study for cancer survivors to help participants to become more active. Studies suggested an association between inactivity and cancer.
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colorectal Cancer
- Trial name
- PATH (NCT03212079)
- Testing
- Mycoach Smart Text, MyCoach on Amazon Alexa
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Johns Hopkins University
Liver Cancer
Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
This research is being done to find how soon the liver cancer may come back and whether proteins or genes in tumor, blood or urine can give us clues of early recurrence.
- Trial name
- NCT00282100
- Testing
- Gefetinib (Iressa)
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Tan Tock Seng Hospital
Colorectal Cancer, Colon Cancer
CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
This study has two portions. The main goal of the Phase I portion of this research study is to see what doses of CB-839 and capecitabine can safely be given to patients without having too many side effects.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
- Trial name
- NCT02861300
- Testing
- CB-839, Capecitabine
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- David Bajor, MD
HepatoCellular Carcinoma
The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.
The current random, double-blind, controlled, clinical trial was designed to evaluate the impact on therapeutic effect and tolerance of treatment for patients with hepatocelluclar carcinoma in transcatheter arterial…
- Trial name
- NCT02987907
- Testing
- Dexamethasone, Normal Saline
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Sun Yat-sen University
Gastric Cancer, Gastroesophageal Junction Cancer
Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer
The combination of Cisplatin and S-1 (CS) achieved a response rate of approximately 45% with the PFS being around 6 months and overall survival time being 13 months in Japanese and Chinese gastric patients.
- Trial name
- NCT01747707
- Testing
- Docetaxel, Cisplatin, S-1
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Carcinoma, Hepatocellular
A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma
Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year.
- Trial name
- THBC002 (NCT00440934)
- Testing
- Amplitude-modulated electromagnetic fields
- Where
- Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pasche, Boris, M.D.
Multiple Primary Lung Cancer, Microbial Colonization
Exploratory Study of the Microbiome of Upper Gastrointestinal in the Pathogenesis of Multiple Primary Lung Cancer
This is an exploratory, single-center, being conducted at Beijing Haidian Hospital in order to detect the relationship between microbiome of upper gastrointestinal and pathogenesis of multiple primary lung cancer.
- Trial name
- NCT06973499
- Testing
- Microbiome Profiling and Symptom Assessment
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Beijing Haidian Hospital
Colorectal Neoplasms
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
This is a single arm, open phase II study to evaluate the efficacy and safety of tislelizumab combined with cetuximab + irinotecan in the treatment of Ras wild-type recurrent and refractory colorectal cancer.
- Trial name
- NCT05143099
- Testing
- TEC
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Zhongshan Hospital
Breast Cancer, Colo-rectal Cancer
A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
The PRO-ACTIVE study aims to develop a clinical-translational program in the field of cancer prevention in all its phases (primary, secondary, and tertiary) to intervene before the clinical and radiological manifestation of the…
- Conditions
- Breast Cancer, Colo-rectal Cancer, Ovarian Cancer, Melanoma (Skin Cancer)
- Trial name
- PRO-ACTIVE (NCT07469709)
- Where
- Italy
- Volunteers
- 850 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Gastrointestinal Microbiome, DNA Methylation
Analysis of Intestinal Microflora Combined With DNA Methylation in Stool to Detect Colorectal Cancer
Introduction: Colorectal cancer (CRC) has the third highest incidence rate and the fourth mortality rate in the world. Traditional colonoscopy as an invasive examination method cannot be widely used in screening for colorectal…
- Conditions
- Gastrointestinal Microbiome, DNA Methylation, Colorectal Neoplasms
- Trial name
- IMMDC (NCT04302363)
- Testing
- Fecal microbiota detection and exfoliated cell gene detection
- Where
- China
- Volunteers
- 500 people
- Sponsor
- WEIDONG LIU，MD
Cholecystitis, Liver Neoplasms
Feasibility Study of Non-Contact Imaging-Based Physiological Monitoring in the Operating Room
This study aims to evaluate the feasibility and accuracy of a non-contact, camera-based physiological monitoring technology in a perioperative setting (including anesthesia induction, surgery, and recovery).Conventional vital…
- Conditions
- Cholecystitis, Liver Neoplasms, Cholelithiasis, Inguinal Hernia
- Trial name
- IBPM (NCT07473687)
- Testing
- Non-contact rPPG software
- Where
- Taiwan
- Volunteers
- 315 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Cholangiocarcinoma, Gall Bladder Carcinoma
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer
This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs.
- Trial name
- ACTICCA-1 (NCT02170090)
- Testing
- Gemcitabine, Cisplatin, Capecitabine
- Where
- 67 sites in Australia, Austria and 6 more
- Volunteers
- 789 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Cancer of Stomach
Role of Routine Nasogastric Decompression After Subtotal Gastrectomy
The aim of the study is to evaluate whether subtotal gastrectomy without post-operative nasogastric decompression is better in terms of early post-operative bowel function and chest complication.
- Trial name
- NCT00164918
- Testing
- nasogastric tube
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese University of Hong Kong
Hepatocellular Carcinoma
Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma
Atezolizumab (anti-programmed death-ligand 1; anti-PD-L1) in conjunction with bevacizumab (anti-vascular endothelial growth factor; anti-VEGF) has become the established standard first-line systemic treatment for unresectable…
- Trial name
- PhotonAB (NCT06339424)
- Testing
- Atezolizumab, Bevacizumab, Photon radiotherapy
- Where
- Taiwan
- Volunteers
- 45 people
- Sponsor
- Chang Gung Memorial Hospital
Non-small Cell Lung Cancer, Esophageal Cancer
Radiation-induced Toxicity of the Heart
Late side effects in radio(chemo)therapy [R(CH)T] pose a critical limitation to patients' overall survival and quality of life. Even though toxicities of the heart are highly relevant for patients with cancer in the thoracic…
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Breast Cancer Female
- Trial name
- CorTox (NCT06986291)
- Testing
- Imaging and biomarkers
- Where
- Germany
- Volunteers
- 325 people
- Sponsor
- Technische Universität Dresden
Hepatocellular Carcinoma
Sorafenib With TACE to Treat Hepatocellular Carcinoma
The purpose of this study is to determine the feasibility to combine sorafenib with transarterial chemoembolisation in patients suffering from hepatocellular carcinoma.The hypothesis is that sorafenib may prevent the development…
- Trial name
- S-TACE (NCT00478374)
- Testing
- Sorafenib, Transarterial chemoembolisation with doxorubicin
- Where
- Switzerland
- Volunteers
- 21 people
- Sponsor
- University of Bern
Hepatocellular Carcinoma
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Trans-arterial chemoembolization (TACE) is the most commonly used therapy for patients with unresectable hepatocellular carcinoma (HCC).
- Trial name
- TAQE (NCT05842174)
- Testing
- Hydroxychloroquine, Lipiodol
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- VA Office of Research and Development
Pancreatic Neoplasms
Discovery of Soluble Biomarkers for Pancreatic Cancer Using Innovative All-Patient Inclusive Methodology
Pancreatic ductal adenocarcinoma (PDAC) remains among cancers with a very poor prognosis (1-year survival <20%). Endoscopic ultrasound with fine needle aspiration (EUS/FNA) is the common examination for all patients with…
- Trial name
- PanEXPEL2 (NCT04370574)
- Testing
- Soluble Biomarkers dosage
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.